Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Lunetta

Showing results (121-130 of 167) with videos related to

Pageof 17
Sort By:
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 15, 2013
Whole-blood global DNA methylation is increased in amyotrophic lateral sclerosis independently of age of onsetLucio Tremolizzo, Paolo Messina, Elisa Conti, et al.
Healthcare (Basel, Switzerland)|March 28, 2025
Timely and Personalized Interventions and Vigilant Care in Neurodegenerative Conditions: The FIT4TeleNEURO Pragmatic TrialFrancesca Baglio, Federica Rossetto, Elisa Gervasoni, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 27, 2016
Clinical exome sequencing in early-onset generalized dystonia and large-scale resequencing follow-upMichael Zech, Sylvia Boesch, Angela Jochim, et al.
Progress in Neurobiology|April 27, 2020
miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosisAlessia Loffreda, Monica Nizzardo, Alessandro Arosio, et al.
Journal of Neurology|June 20, 2020
The Italian multicenter experience with edaravone in amyotrophic lateral sclerosisChristian Lunetta, Cristina Moglia, Andrea Lizio, et al.
Medicine|June 15, 2018
Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)Jessica Mandrioli, Roberto D'Amico, Elisabetta Zucchi, et al.
Muscle & Nerve|June 9, 2025
Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of TreatmentAngela Genge, Gary L Pattee, Gen Sobue, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 2, 2025
Time-to-event prediction in ALS using a landmark modeling approach, using the ALS Natural History Consortium datasetDavid Schneck, Andres Arguedas, Annette Xenopoulos-Oddsson, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 14, 2025
Risk prediction for ALS using semi-competing risk models with applications to the ALS Natural History Consortium datasetAndres Arguedas, David Schneck, Erjia Cui, et al.
Brain : a Journal of Neurology|January 25, 2022
Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosisNilo Riva, Francesco Gentile, Federica Cerri, et al.
Pageof 17

Showing results (121-130 of 167) with videos related to

Sort By:
Pageof 17
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 15, 2013
Whole-blood global DNA methylation is increased in amyotrophic lateral sclerosis independently of age of onsetLucio Tremolizzo, Paolo Messina, Elisa Conti, et al.
Healthcare (Basel, Switzerland)|March 28, 2025
Timely and Personalized Interventions and Vigilant Care in Neurodegenerative Conditions: The FIT4TeleNEURO Pragmatic TrialFrancesca Baglio, Federica Rossetto, Elisa Gervasoni, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 27, 2016
Clinical exome sequencing in early-onset generalized dystonia and large-scale resequencing follow-upMichael Zech, Sylvia Boesch, Angela Jochim, et al.
Progress in Neurobiology|April 27, 2020
miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosisAlessia Loffreda, Monica Nizzardo, Alessandro Arosio, et al.
Journal of Neurology|June 20, 2020
The Italian multicenter experience with edaravone in amyotrophic lateral sclerosisChristian Lunetta, Cristina Moglia, Andrea Lizio, et al.
Medicine|June 15, 2018
Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)Jessica Mandrioli, Roberto D'Amico, Elisabetta Zucchi, et al.
Muscle & Nerve|June 9, 2025
Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of TreatmentAngela Genge, Gary L Pattee, Gen Sobue, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 2, 2025
Time-to-event prediction in ALS using a landmark modeling approach, using the ALS Natural History Consortium datasetDavid Schneck, Andres Arguedas, Annette Xenopoulos-Oddsson, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 14, 2025
Risk prediction for ALS using semi-competing risk models with applications to the ALS Natural History Consortium datasetAndres Arguedas, David Schneck, Erjia Cui, et al.
Brain : a Journal of Neurology|January 25, 2022
Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosisNilo Riva, Francesco Gentile, Federica Cerri, et al.
Pageof 17